Efficacy and Safety Overview

^aThrough Week 24 with DUPIXENT 300 mg Q2W + SOC (n=64) vs placebo + SOC (n=68) (0.20 vs 1.04; rate ratio: 0.19 [95% CI: 0.07, 0.56]) (baseline blood EOS ≥300 cells/µL, DRI12544, secondary endpoint).¹

^b470 mL improvement at Week 52 from baseline in pre-bronchodilator FEV₁ with DUPIXENT 200 mg Q2W + SOC (n=264) vs 170 mL improvement with placebo + SOC (n=148) (baseline blood EOS ≥300 cells/µL, QUEST, secondary endpoint). ~72% of the total FEV₁ improvement was seen after the first dose at Week 2.^1,4

^c75% of patients had improved ACQ-5 (asthma control) scores with DUPIXENT 200 mg Q2W + SOC vs 67% with placebo + SOC (OR: 1.46 [95% CI: 0.90, 2.35]) (baseline blood EOS ≥300 cells/µL, QUEST, secondary endpoint).¹

^d71% of patients had improved AQLQ(S) (quality of life) scores with DUPIXENT 200 mg Q2W + SOC vs 55% with placebo + SOC (OR: 2.02 [95% CI: 1.24, 3.32]) (baseline blood EOS ≥300 cells/µL, QUEST, secondary endpoint).¹

^eACQ-5 and AQLQ(S) were assessed as secondary endpoints but were ordered after the point at which the hierarchical break occurred. Results are descriptive.³

^fThe asthma development program for patients aged 12 years and older included three randomized, double-blind, placebo-controlled, parallel-group, multicenter trials (DRI12544, QUEST, and VENTURE) of 24 to 52 weeks in treatment duration, which enrolled a total of 2888 subjects.¹